美國Gen-Probe  www.gen-probe.com
Gen-Probe公司（美國分子生物學檢測方法創(chuàng)始公司之一，是FDA指定的為美國血庫作檢測的公司），位于美國圣地亞哥，是一個在開發(fā)、制造和商業(yè)化基于它的專利基因探針技術的診斷產(chǎn)品的公認的世界領導公司。
　　在用基因探針試驗檢測微生物的領域中，公司已經(jīng)取得41個FDA許可，包括那些可致性傳播疾病、肺結核、咽喉炎、肺炎和真菌感染等。
　　Gen-Probe現(xiàn)在正在開發(fā)病毒核酸試驗用于篩查血源中的HIV-1、丙肝和乙肝病毒，并同此領域的世界上領導公司如bioMérieux,Chiron, 和Bayer保持合作關系。

2012年Hologic 37.2億美元收購Gen-Probe

Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) used primarily to diagnose human diseases and screen donated human blood. NATs harness the power of biotechnology to detect diseases more rapidly and/or accurately than older testing methods, and have therefore become one of the fastest-growing segments of the in vitro diagnostics industry.
Gen-Probe markets a broad portfolio of products that use the Company's patented technologies to detect infectious microorganisms, including those causing sexually transmitted diseases (STDs), tuberculosis, strep throat, pneumonia and fungal infections. Gen-Probe's key clinical diagnostics products include the APTIMA COMBO 2® and PACE® assays, which are used to detect the common STDs Chlamydia and gonorrhea.
In blood screening, Gen-Probe developed and manufactures the PROCLEIX® assay, which is used to detect HIV-1 and the hepatitis C virus (HCV) in donated human blood; the PROCLEIX ULTRIO® assay, which detects the hepatitis B virus in addition to HIV-1 and HCV; and the PROCLEIX WNV (West Nile virus) assay. Gen-Probe's blood screening products are marketed worldwide by Chiron, a business unit of Novartis Vaccines and Diagnostics, Inc.
Gen-Probe also has a robust development pipeline. For example, the Company is developing NATs to detect prostate cancer, drug-resistant hospital infections, and human papillomavirus, which causes cervical cancer. In addition, Gen-Probe is working with General Electric and Millipore to develop NATs that detect microorganisms that commonly contaminate industrial processes.
Several of Gen-Probe's current and future molecular diagnostic tests can be performed on the Company's TIGRIS® instrument, the only fully automated, high-throughput NAT system for diagnostics and blood screening.
Gen-Probe is headquartered in San Diego and employs approximately 1,000 people.